Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Drops By 62.4%

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 1,660,000 shares, a drop of 62.4% from the February 13th total of 4,420,000 shares. Approximately 8.8% of the company’s shares are short sold. Based on an average daily trading volume, of 8,860,000 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of ProPhase Labs in a research report on Tuesday, February 25th. They issued a “sell” rating for the company.

ProPhase Labs Stock Down 7.8 %

NASDAQ:PRPH traded down $0.03 during mid-day trading on Friday, hitting $0.39. The company had a trading volume of 679,006 shares, compared to its average volume of 2,368,002. The business has a fifty day simple moving average of $0.46 and a 200-day simple moving average of $1.26. The firm has a market capitalization of $9.37 million, a price-to-earnings ratio of -0.31 and a beta of -0.53. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48.

Institutional Investors Weigh In On ProPhase Labs

Hedge funds have recently modified their holdings of the stock. Sheets Smith Wealth Management acquired a new stake in ProPhase Labs in the fourth quarter valued at approximately $158,000. Perritt Capital Management Inc boosted its stake in shares of ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after purchasing an additional 107,068 shares during the period. Warberg Asset Management LLC acquired a new stake in ProPhase Labs during the 4th quarter valued at $77,000. Renaissance Technologies LLC increased its stake in ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after buying an additional 71,375 shares during the period. Finally, HighTower Advisors LLC lifted its holdings in ProPhase Labs by 32.2% in the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after buying an additional 57,736 shares in the last quarter. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.